

Consumer Update

Jan 2022

Voriconazole – Risk of drug-drug interaction with Lurasidone since it may result in significant increase in Lurasidone exposure

[EDA performs Label Update to include the following:](#)

Drug interactions

Voriconazole increases levels of Lurasidone, as the metabolism of Lurasidone can be Decreased when combined with Voriconazole.

Coadministration of voriconazole with lurasidone is contraindicated since significant increases in lurasidone exposure have the potential for serious adverse reactions.

[Background](#)

Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:

Treatment of invasive aspergillosis.

Treatment of candidaemia in non-neutropenic patients.

Treatment of fluconazole-resistant serious invasive Candida infections (including C.krusei).

Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.

Voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.

References: FDA ([Click here](#))